Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/2613
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | GEUSENS, Piet | - |
dc.contributor.author | Truitt, K. | - |
dc.contributor.author | Sfikakis, P. | - |
dc.contributor.author | Zhao, P.L. | - |
dc.contributor.author | DeTora, L. | - |
dc.contributor.author | Shingo, S. | - |
dc.contributor.author | Lau, C.S. | - |
dc.contributor.author | Kalla, A. | - |
dc.contributor.author | Tate, G. | - |
dc.date.accessioned | 2007-11-15T13:50:27Z | - |
dc.date.available | 2007-11-15T13:50:27Z | - |
dc.date.issued | 2002 | - |
dc.identifier.citation | SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 31(4). p. 230-238 | - |
dc.identifier.issn | 0300-9742 | - |
dc.identifier.uri | http://hdl.handle.net/1942/2613 | - |
dc.description.abstract | Objective: To evaluate the efficacy and tolerability of rofecoxib 25 mg and 50 mg once daily versus placebo and naproxen 500 mg twice daily in patients with RA. Methods: Eligible patients were randomized (double-blind) to placebo (n = 289), rofecoxib 25 mg (n = 306), 50 mg (n = 286) once daily, or naproxen (n = 142) for 12 weeks. Efficacy assessments included the ACR core set, with prespecified primary endpoints: patient and investigator global assessments of disease activity, tender and swollen joint counts. Investigator-reported adverse experiences, routine laboratory and vital sign measurements were monitored. Results: Rofecoxib 25 mg, 50 mg, and naproxen provided similar treatment effects, significantly different from placebo, consistent with improvement, for all primary endpoints. Effects were evident at the earliest assessment (week 2) and sustained for 12 weeks. All treatments were generally well-tolerated. Conclusions: Rofecoxib 25 mg once daily had similar efficacy to naproxen 500 mg twice daily (a standard dose). No additional benefit was seen with 50 mg rofecoxib. | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS AS | - |
dc.subject.other | rofecoxib; COX-2; RA; NSAID; naproxen; randomized trial | - |
dc.title | A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 238 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | 230 | - |
dc.identifier.volume | 31 | - |
local.format.pages | 9 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Merck & Co Inc, Merck Res Labs, Rahway, NJ 07065 USA. Univ Hosp, Maastricht, Netherlands. Limburgs Univ Centrum, Diepenbeek, Belgium. Liko Gen Hosp, Athens, Greece. Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China. Old Groote Schuur Hosp, Cape Town, South Africa. Sanatorio Otamendi, Buenos Aires, DF, Argentina.DeTora, L, Merck & Co Inc, Merck Res Labs, 126 E Lincoln Ave,RY 32-645, Rahway, NJ 07065 USA. | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.bibliographicCitation.oldjcat | A1 | - |
dc.identifier.doi | 10.1080/030097402320318431 | - |
dc.identifier.isi | 000177729700009 | - |
item.fullcitation | GEUSENS, Piet; Truitt, K.; Sfikakis, P.; Zhao, P.L.; DeTora, L.; Shingo, S.; Lau, C.S.; Kalla, A. & Tate, G. (2002) A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis. In: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 31(4). p. 230-238. | - |
item.fulltext | No Fulltext | - |
item.validation | ecoom 2003 | - |
item.contributor | GEUSENS, Piet | - |
item.contributor | Truitt, K. | - |
item.contributor | Sfikakis, P. | - |
item.contributor | Zhao, P.L. | - |
item.contributor | DeTora, L. | - |
item.contributor | Shingo, S. | - |
item.contributor | Lau, C.S. | - |
item.contributor | Kalla, A. | - |
item.contributor | Tate, G. | - |
item.accessRights | Closed Access | - |
crisitem.journal.issn | 0300-9742 | - |
crisitem.journal.eissn | 1502-7732 | - |
Appears in Collections: | Research publications |
SCOPUSTM
Citations
37
checked on Sep 7, 2020
WEB OF SCIENCETM
Citations
31
checked on Sep 25, 2024
Page view(s)
58
checked on Jun 14, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.